Updated:
Walter and Eliza Hall Institute of Medical Research
Walter and Eliza Hall Institute of Medical Research: A leading Australian biomedical research institute founded in 1915 with a focus on immunology and...
Walter and Eliza Hall Institute of Medical Research
The Walter and Eliza Hall Institute of Medical Research was founded in 1915 with an endowment from the Hall family. It was the first medical research institute in Australia and has since become a leading center for immunology, cancer biology, and infectious disease research. The institute pursues a strategy of fundamental cellular and molecular biology, with a strong translational pipeline targeting cancer, autoimmune disorders, and infections. It has produced landmark findings including the discovery of the BH3-mimetic drug venetoclax, co-developed with Genentech and Roche, for treating chronic lymphocytic leukemia. Its research spans the life sciences, with active programs in bioinformatics, structural biology, and clinical collaborations. With over 1,500 scientists and staff, the institute is one of Australia's largest medical research bodies. It operates as an independent not-for-profit affiliated with the University of Melbourne and the Royal Melbourne Hospital. In 2024, the institute continued its research on immune-checkpoint inhibitors for cancer therapy, a key area of global oncology investment. The institute's structural differentiator is its hybrid model: a publicly-funded philanthropic research entity that licenses its drug discoveries to pharmaceutical partners. This allows it to create revenue streams from intellectual property while maintaining academic freedom. Its governance includes a board of trustees and a scientific advisory committee, ensuring focus on long-term discovery over commercial pressures.
General information
Firm type
Research Institute
Year founded
1915
AUM
Undisclosed
Location
Region
Oceania
Country
Australia
City
Parkville
Corporate office
Parkville, Victoria, Australia
Additional offices
Melbourne, Australia
Principals
Ken Smith
Director
Doug Hilton
Former Director
Sector focus
Frequently asked questions
Who runs the Walter and Eliza Hall Institute?
Ken Smith has served as Director since 2025, succeeding Doug Hilton. The director oversees a research portfolio spanning multiple disease areas, with support from a board of trustees and a scientific advisory committee (per the institute's official communications).
How is the institute funded?
The institute receives funding from the Australian government through the National Health and Medical Research Council, as well as philanthropic donations and revenue from drug licensing agreements. Its endowment from the Hall family provides ongoing support (public record).
Does the institute have an investment arm or manage external capital?
The institute does not appear to manage external capital in the manner of a family office or asset manager. It is a non-profit research organization that generates revenue mainly from government grants, philanthropy, and licensing of intellectual property to pharmaceutical partners such as Roche and Genentech (public record).
What is the institute's relationship with the University of Melbourne?
The institute is affiliated with the University of Melbourne and the Royal Melbourne Hospital. It is an independent entity but collaborates closely with the university on research projects and training. The affiliation allows shared resources and joint appointments (public record).
What are the institute's most notable scientific discoveries?
The institute is a pioneer in immunology, known for discovering the cytokine GM-CSF and for developing the BH3-mimetic drug venetoclax, which revolutionized the treatment of chronic lymphocytic leukemia. These discoveries have led to multiple clinical trials and commercial partnerships (per the institute's official communications).
Does the institute have a venture capital or investment vehicle?
The institute does not publicly report operating an investment vehicle such as a venture capital fund. It relies on its commercial arm, Walter and Eliza Hall Institute of Medical Research PTY LTD, to manage intellectual property licensing and technology transfer (public record).
What investment stages does the institute target in its research?
The institute focuses on basic research and early-stage drug discovery rather than later-stage clinical investments. It aims to move discoveries from the bench to proof-of-concept studies, after which it licenses them to pharmaceutical companies for further development (per the firm's official communications).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: